Results 261 to 270 of about 4,472,659 (361)
Cross-modal neuroplasticity in partial hearing loss: a mini-review. [PDF]
Aguiar PV, Preman J, Paul BT.
europepmc +1 more source
Advantages of Exome Sequencing Over Panel Testing for Individuals With a Seizure Indication
ABSTRACT Objective Our aim was to investigate the advantages of exome sequencing versus panel testing for patients with unexplained seizures. Methods We reviewed the diagnostic outcomes of exome sequencing by a commercial genetics laboratory for more than 16 000 individuals with a clinical history of seizures or suspected seizures.
Michelle M. Morrow +8 more
wiley +1 more source
The effect of sample type on genetic testing completion in pediatric congenital hearing loss patients. [PDF]
Adams B, Lichten L, Heyward A, Govil N.
europepmc +1 more source
Hypertension is a known modifiable risk factor for Alzheimer’s disease and related dementia (ADRD). However, it is unknown how variance in hypertension control, antihypertensive medications, and social determinants of health, such as social deprivation index (SDI), influence the risk of developing ADRD.
Eissa A. Jafari +6 more
wiley +1 more source
Hearing loss in the young-old is associated with increased risk for Alzheimer's disease and vascular dementia. [PDF]
Francis L +11 more
europepmc +1 more source
The Bulletin of the Ecological Society of America, EarlyView.
Shersingh Joseph Tumber‐Dávila +5 more
wiley +1 more source
Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted.
Tara Lazetic +4 more
wiley +1 more source

